Celltrion Will Present Infliximab Data at UEG Week 2026
The company will showcase new clinical evidence for its infliximab portfolio during an upcoming October 18 symposium.
Updated on Oct. 15, 2026 in Biotech
Live Poll
Do you trust that pharmaceutical companies prioritize patient access when developing new treatment formulations?
Celltrion is set to host a symposium and multiple educational sessions at UEG Week 2026 on October 18. The company will highlight its infliximab portfolio, including clinical evidence for its Remsima SC monotherapy.
Why it matters
The presentations aim to provide healthcare professionals with updated clinical insights into the use of subcutaneous and intravenous infliximab for inflammatory bowel disease. These sessions support Celltrion's ongoing strategy to expand its global footprint in the IBD treatment market.
Celltrion's CT-P13 SC formulation utilizes a 120mg fixed dose, which has received regulatory approval in 60 countries including the UK, US, and EU. The company recently expanded its European portfolio with the launch of a new Remsima IV liquid formulation.
The players
Celltrion
Celltrion is a global biopharmaceutical company that specializes in the research, development, and manufacturing of monoclonal antibody biosimilars.
Professor Peter M. Irving
Professor Peter M. Irving is an expert in gastroenterology who is scheduled to chair the upcoming Celltrion symposium at UEG Week.
Professor Irina Blumenstein
Professor Irina Blumenstein is a medical professional who will present clinical evidence on Remsima SC monotherapy.
The details
Professor Peter M. Irving will chair the symposium on October 18, while Professor Irina Blumenstein is scheduled to present data regarding Remsima SC monotherapy. The sessions will also cover the company's broader IBD treatment lineup, which includes the SteQeyma and Yuflyma products.
Timeline
October 18, 2026: Celltrion hosts a symposium on subcutaneous infliximab.
The Tech Race
The transition from traditional intravenous delivery to subcutaneous options represents a significant shift in IBD management technology. This move allows manufacturers like Celltrion to challenge legacy infusion-only standards and increase their competitive position in the global market.
For patients and providers, these developments could mean increased access to subcutaneous treatment options that provide greater flexibility than traditional intravenous infusions. The expansion of these formulations aims to simplify treatment regimens for those managing inflammatory bowel disease.
The takeaway
The pivot toward subcutaneous formulations highlights a broader industry trend of prioritizing patient convenience through pharmaceutical innovation. Healthcare providers should monitor these clinical updates to understand the evolving efficacy profiles of non-traditional administration methods.
Further reading
Learn more about the latest industry developments in Biotech.
Live Poll
Do you trust that pharmaceutical companies prioritize patient access when developing new treatment formulations?
